Omnicell (OMCL)

NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-10-23

$37.75+1.75%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Omnicell’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-1.7%

+10% or more+5%0%−5%−10% or less

2.09 → 2.06 EPS · FY ending Dec 31, 2027 · 5 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 5 to 5; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	310.48M
EPS	—	0.368
Annual ending 2026-12-31
Revenue	—	1.24B
EPS	—	2.269
Annual ending 2027-12-31
Revenue	—	1.29B
EPS	—	2.055

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash from operating activities at or above $55 million quarterly	Operating income improved sharply to $17 million in Q1 2026 from $0.4 million in Q4 2025.	Recovered	Cash from operations falls below $30 million quarterly	Cash from operations: $69.546M FY2026-Q2; GAAP. Published target: >= $55 million cash from operations. Target period is not explicitly aligned with this observation. Source published Aug 5, 202669,546,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Cash from operating activities rose from $42.8 million in 2025-Q2 to $68.3 million in 2026-Q2, and from $25.9 million in 2025-Q1 to $54.5 million in 2026-Q1. This reflects delivering improved cash flow generation consistent with management's stated focus. Delivery assessment Oct 24, 2026
EPS at or above $1.9 per share for FY26	The company’s EPS guidance for 2026 is raised to $1.9 per share.	Broken	EPS guidance falls below $1.8 per share for FY26	Diluted EPS: $0.52 per share FY2026-Q2; GAAP. Published target: >= $1.9 EPS. Target period is not explicitly aligned with this observation. Source published Aug 5, 20260.52 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 876a7c7d-326a-4741-841a-c0e41528cc79. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income improvement to at least $17 million quarterly	Operating income improved sharply to $17 million in Q1 2026 from $0.4 million in Q4 2025.	Broken	Operating income falls below $8 million quarterly	Operating income: $32.449M FY2026-Q2; GAAP. Published target: >= $17 million operating income. Target period is not explicitly aligned with this observation. Source published Aug 5, 202632,449,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 876a7c7d-326a-4741-841a-c0e41528cc79. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Operating income improved significantly from $0.4 million in 2025-Q4 to $32.4 million in 2026-Q2. Non-GAAP EBITDA rose from $38 million in Q2 2025 to $67 million in Q2 2026. Management's focus on disciplined cost management aligns with improving profitability metrics, indicating delivering progress. Delivery assessment Oct 24, 2026
Total revenue growth at or above 5% annually	A primary condition in Omnicell's published investment case. The stated target is >=5% YoY revenue growth.	Broken	YoY revenue growth falls below 5% in FY26	Revenue growth: 7.45% FY2026-Q2; GAAP. Published target: >=5% YoY revenue growth. Target period is not explicitly aligned with this observation. Source published Aug 5, 20267.449701 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 876a7c7d-326a-4741-841a-c0e41528cc79. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Revenue grew from $269.7 million in 2025-Q1 to $312.2 million in 2026-Q2, a 7% increase year-over-year in Q2 and 15% in Q1. Management consistently emphasized growth driven by connected devices and SaaS offerings, and the financials show delivering top-line growth. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$2.06

$2.19 → $2.06 · observed estimates

FY2027 revenue$1.29B

$1.32B → $1.29B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$2.19	$1,315,262,060	8 / 8
2026-07-25	$2.19	$1,315,262,060	8 / 8
2026-07-26	$2.19	$1,315,262,060	8 / 8
2026-07-27	$2.19	$1,315,262,060	8 / 8
2026-07-28	$2.19	$1,315,262,061	5 / 6
2026-07-29	$2.19	$1,315,262,060	8 / 8
2026-07-30	$2.19	$1,315,262,060	8 / 8
2026-07-31	$2.19	$1,300,512,314	5 / 6
2026-08-01	$2.19	$1,300,512,314	5 / 6
2026-08-02	$2.16	$1,292,927,190	8 / 8
2026-08-03	$2.16	$1,292,954,314	5 / 6
2026-08-04	$2.16	$1,292,954,314	5 / 6
2026-08-05	$2.09	$1,288,278,560	8 / 8
2026-08-06	$2.16	$1,292,954,314	5 / 6
2026-08-07	$2.16	$1,292,954,314	5 / 6
2026-08-08	$2.09	$1,288,278,560	8 / 8
2026-08-09	$2.09	$1,288,278,560	8 / 8
2026-08-10	$2.16	$1,292,954,314	5 / 6
2026-08-12	$2.16	$1,292,954,314	5 / 6
2026-08-13	$2.09	$1,288,278,560	8 / 8
2026-08-14	$2.16	$1,292,954,314	5 / 6
2026-08-15	$2.16	$1,292,954,314	5 / 6
2026-08-16	$2.16	$1,292,954,314	5 / 6
2026-08-17	$2.16	$1,292,954,314	5 / 6
2026-08-18	$2.16	$1,292,954,314	5 / 6
2026-08-19	$2.16	$1,292,954,314	5 / 6
2026-08-20	$2.09	$1,288,305,689	5 / 6
2026-08-21	$2.09	$1,288,305,689	5 / 6
2026-08-22	$2.09	$1,288,305,689	5 / 6
2026-08-23	$2.09	$1,288,305,689	5 / 6
2026-08-24	$2.09	$1,288,305,689	5 / 6
2026-08-25	$2.09	$1,288,305,689	5 / 6
2026-08-26	$2.09	$1,288,305,689	5 / 6
2026-08-27	$2.09	$1,288,305,689	5 / 6
2026-08-28	$2.09	$1,288,305,689	5 / 6
2026-08-29	$2.09	$1,288,305,689	5 / 6
2026-08-30	$2.09	$1,288,305,689	5 / 6
2026-08-31	$2.09	$1,288,305,689	5 / 6
2026-09-01	$2.09	$1,288,305,689	5 / 6
2026-09-02	$2.09	$1,288,305,689	5 / 6
2026-09-03	$2.09	$1,288,305,689	5 / 6
2026-09-04	$2.09	$1,288,305,689	5 / 6
2026-09-05	$2.09	$1,288,305,689	5 / 6
2026-09-06	$2.09	$1,288,305,689	5 / 6
2026-09-07	$2.09	$1,288,305,689	5 / 6
2026-09-08	$2.09	$1,288,305,689	5 / 6
2026-09-09	$2.09	$1,288,305,689	5 / 6
2026-09-10	$2.09	$1,288,305,689	5 / 6
2026-09-11	$2.09	$1,288,305,689	5 / 6
2026-09-12	$2.09	$1,288,305,689	5 / 6
2026-09-13	$2.09	$1,288,305,689	5 / 6
2026-09-14	$2.09	$1,288,305,689	5 / 6
2026-09-15	$2.09	$1,288,305,689	5 / 6
2026-09-16	$2.09	$1,288,305,689	5 / 6
2026-09-17	$2.09	$1,288,305,689	5 / 6
2026-09-18	$2.09	$1,288,305,689	5 / 6
2026-09-19	$2.09	$1,288,305,689	5 / 6
2026-09-20	$2.09	$1,288,305,689	5 / 6
2026-09-21	$2.09	$1,288,305,689	5 / 6
2026-09-22	$2.09	$1,288,305,689	5 / 6
2026-09-23	$2.09	$1,288,305,689	5 / 6
2026-09-24	$2.09	$1,288,305,689	5 / 6
2026-09-25	$2.09	$1,288,305,689	5 / 6
2026-09-26	$2.09	$1,288,305,689	5 / 6
2026-09-27	$2.09	$1,288,305,689	5 / 6
2026-09-28	$2.09	$1,288,305,689	5 / 6
2026-09-29	$2.09	$1,288,305,689	5 / 6
2026-09-30	$2.09	$1,288,305,689	5 / 6
2026-10-01	$2.09	$1,288,305,689	5 / 6
2026-10-02	$2.09	$1,288,305,689	5 / 6
2026-10-03	$2.09	$1,288,305,689	5 / 6
2026-10-04	$2.09	$1,288,305,689	5 / 6
2026-10-05	$2.09	$1,288,305,689	5 / 6
2026-10-06	$2.09	$1,288,305,689	5 / 6
2026-10-07	$2.09	$1,288,305,689	5 / 6
2026-10-08	$2.09	$1,288,305,689	5 / 6
2026-10-09	$2.09	$1,288,305,689	5 / 6
2026-10-10	$2.09	$1,288,305,689	5 / 6
2026-10-11	$2.09	$1,288,305,689	5 / 6
2026-10-12	$2.09	$1,288,305,689	5 / 6
2026-10-13	$2.09	$1,288,305,689	5 / 6
2026-10-14	$2.09	$1,288,305,689	5 / 6
2026-10-15	$2.06	$1,287,969,314	5 / 6
2026-10-16	$2.06	$1,287,969,314	5 / 6
2026-10-17	$2.06	$1,287,969,314	5 / 6
2026-10-18	$2.06	$1,287,969,314	5 / 6
2026-10-19	$2.06	$1,287,969,314	5 / 6
2026-10-20	$2.06	$1,287,969,314	5 / 6
2026-10-21	$2.06	$1,287,969,314	5 / 6
2026-10-22	$2.06	$1,287,969,314	5 / 6
2026-10-23	$2.06	$1,287,969,314	5 / 6
2026-10-24	$2.06	$1,287,969,314	5 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	1
2026-06-01	7	1
2026-07-01	7	1
2026-08-01	7	1
2026-09-01	7	1
2026-10-01	7	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash from operating activities at or above $55 million quarterlyCash from operations: $69.546M
EPS at or above $1.9 per share for FY26Published status: Broken
Operating income improvement to at least $17 million quarterlyPublished status: Broken
Total revenue growth at or above 5% annuallyPublished status: Broken

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.5%Typical daily move · historical

Downside history

-37.3%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Omnicell outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-and-profitability improvement story, rather than an established profitable compounder. The multi-year view is intact, with recent financial performance holding up, but the business remains loss-making overall and risk is elevated.

What's priced into Omnicell

OMCL is assessed as cheap versus peers, while the expectations gap is close to neutral. The evidence labels current pricing as justified and shows low valuation fragility, so it does not point to unusually stretched expectations.

What the fundamentals likely do

Near term, management’s repeated focus on revenue growth, operating profitability, and cash generation is supported by improving results. Revenue grew year over year in Q2 2026, operating income and non-GAAP EBITDA rose, and operating cash flow increased; however, erratic earnings surprises and possible guidance changes remain risks.

What Omnicell hinges on

Over the next few quarters, the thesis hinges on continued growth and profitability progress, with the next guidance update an important check. A guidance cut or further weakening in jobs data could weigh on the business context, while continued strength from healthcare sector peers would support a more favorable backdrop.